FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4236361077> ?p ?o ?g. }

• W4236361077 abstract "<h3>Background</h3> Aberrant expression of the RON receptor tyrosine kinase is a pathogenic feature and a validated drug target in various types of cancers. Currently, therapeutic antibodies targeting RON for cancer therapy are under intensive evaluation. Here we report the development and validation of a novel humanized anti-RON antibody-drug conjugate for cancer therapy. <h3>Methods</h3> Antibody humanization was achieved by grafting sequences of complementarity-determining regions from mouse monoclonal antibody Zt/g4 into human IgG1/κ acceptor frameworks. The selected humanized Zt/g4 subclone H1L3 was conjugated with monomethyl auristatin E using a dipeptide linker to form H-Zt/g4-MMAE. Pharmacokinetic analysis of H-Zt/g4-MMAE was determined using hydrophobic interaction chromatography and a MMAE ADC ELISA kit. Biochemical and biological assays were used for measuring RON expression, internalization, cell viability and death. Therapeutic efficacies of H-Zt/g4-MMAE were validated in vivo using three pancreatic cancer xenograft models. Toxicological activities of H-Zt/g4-MMAE were determined in mouse and cynomolgus monkey. <h3>Results</h3> H-Zt/g4-MMAE had a drug to antibody ratio of 3.77:1 and was highly stable in human plasma with a dissociation rate less than 5% within a 20 day period. H-Zt/g4-MMAE displayed a favorable pharmacokinetic profile in both mouse and cynomolgus monkey. In vitro, H-Zt/g4-MMAE induced RON internalization, which results in killing of pancreatic cancer cells with IC₅₀ values at 10–20 nM. In vivo<i>,</i> H-Zt/g4-MMAE inhibited pancreatic cancer xenograft growth with tumoristatic concentrations at 1~3 mg/kg bodyweight. Significantly, H-Zt/g4-MMAE eradicated tumors across multiple xenograft models regardless their chemoresistant and metastatic statuses. Moreover, H-Zt/g4-MMAE inhibited and eradicated xenografts mediated by pancreatic cancer stem-like cells and by primary cells from patient-derived tumors. Toxicologically, H-Zt/g4-MMAE is well tolerated in mice up to 60 mg/kg. In cynomolgus monkey, H-Zt/g4-MMAE up to 30 mg/kg had a manageable and reversible toxicity profile. <h3>Conclusions</h3> H-Zt/g4-MMAE is superior in eradication of pancreatic cancer xenografts with favorable pharmacokinetic profiles and manageable toxicological activities. These findings warrant the transition of H-Zt/g4-MMAE into clinical trials in the future." @default.
• W4236361077 created "2022-05-12" @default.
• W4236361077 creator A5001244198 @default.
• W4236361077 creator A5013289378 @default.
• W4236361077 creator A5019038275 @default.
• W4236361077 creator A5020720070 @default.
• W4236361077 creator A5024421837 @default.
• W4236361077 creator A5028617332 @default.
• W4236361077 creator A5043666735 @default.
• W4236361077 creator A5048818909 @default.
• W4236361077 creator A5066037517 @default.
• W4236361077 creator A5071860009 @default.
• W4236361077 creator A5081214301 @default.
• W4236361077 creator A5086932313 @default.
• W4236361077 date "2019-03-14" @default.
• W4236361077 modified "2023-10-12" @default.
• W4236361077 title "Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy" @default.
• W4236361077 cites W1546481233 @default.
• W4236361077 cites W1749752941 @default.
• W4236361077 cites W1934793957 @default.
• W4236361077 cites W1963720869 @default.
• W4236361077 cites W1966828606 @default.
• W4236361077 cites W1972514043 @default.
• W4236361077 cites W1983483937 @default.
• W4236361077 cites W1984101180 @default.
• W4236361077 cites W1987301058 @default.
• W4236361077 cites W1997696802 @default.
• W4236361077 cites W2013878853 @default.
• W4236361077 cites W2019264784 @default.
• W4236361077 cites W2019291236 @default.
• W4236361077 cites W2031491298 @default.
• W4236361077 cites W2033247490 @default.
• W4236361077 cites W2035479572 @default.
• W4236361077 cites W2050738379 @default.
• W4236361077 cites W2053150767 @default.
• W4236361077 cites W2064651476 @default.
• W4236361077 cites W2078343277 @default.
• W4236361077 cites W2081939392 @default.
• W4236361077 cites W2083285346 @default.
• W4236361077 cites W2087836279 @default.
• W4236361077 cites W2092225298 @default.
• W4236361077 cites W2095805442 @default.
• W4236361077 cites W2097644281 @default.
• W4236361077 cites W2100751052 @default.
• W4236361077 cites W2102072877 @default.
• W4236361077 cites W2104501515 @default.
• W4236361077 cites W2118942065 @default.
• W4236361077 cites W2124514746 @default.
• W4236361077 cites W2129875426 @default.
• W4236361077 cites W2130522236 @default.
• W4236361077 cites W2147525904 @default.
• W4236361077 cites W2152538957 @default.
• W4236361077 cites W2160393730 @default.
• W4236361077 cites W2171620027 @default.
• W4236361077 cites W2194390860 @default.
• W4236361077 cites W2312309812 @default.
• W4236361077 cites W2336243671 @default.
• W4236361077 cites W2430472630 @default.
• W4236361077 cites W2513421068 @default.
• W4236361077 cites W2518228338 @default.
• W4236361077 cites W2583420974 @default.
• W4236361077 cites W2742314046 @default.
• W4236361077 cites W2768583786 @default.
• W4236361077 cites W2808377781 @default.
• W4236361077 cites W2811379362 @default.
• W4236361077 cites W2894948154 @default.
• W4236361077 cites W62114904 @default.
• W4236361077 doi "https://doi.org/10.1186/s40425-019-0525-0" @default.
• W4236361077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30871619" @default.
• W4236361077 hasPublicationYear "2019" @default.
• W4236361077 type Work @default.
• W4236361077 citedByCount "18" @default.
• W4236361077 countsByYear W42363610772019 @default.
• W4236361077 countsByYear W42363610772020 @default.
• W4236361077 countsByYear W42363610772021 @default.
• W4236361077 countsByYear W42363610772022 @default.
• W4236361077 countsByYear W42363610772023 @default.
• W4236361077 crossrefType "journal-article" @default.
• W4236361077 hasAuthorship W4236361077A5001244198 @default.
• W4236361077 hasAuthorship W4236361077A5013289378 @default.
• W4236361077 hasAuthorship W4236361077A5019038275 @default.
• W4236361077 hasAuthorship W4236361077A5020720070 @default.
• W4236361077 hasAuthorship W4236361077A5024421837 @default.
• W4236361077 hasAuthorship W4236361077A5028617332 @default.
• W4236361077 hasAuthorship W4236361077A5043666735 @default.
• W4236361077 hasAuthorship W4236361077A5048818909 @default.
• W4236361077 hasAuthorship W4236361077A5066037517 @default.
• W4236361077 hasAuthorship W4236361077A5071860009 @default.
• W4236361077 hasAuthorship W4236361077A5081214301 @default.
• W4236361077 hasAuthorship W4236361077A5086932313 @default.
• W4236361077 hasBestOaLocation W42363610771 @default.
• W4236361077 hasConcept C112705442 @default.
• W4236361077 hasConcept C121608353 @default.
• W4236361077 hasConcept C126322002 @default.
• W4236361077 hasConcept C139770010 @default.
• W4236361077 hasConcept C150903083 @default.
• W4236361077 hasConcept C153911025 @default.
• W4236361077 hasConcept C159654299 @default.
• W4236361077 hasConcept C170493617 @default.
• W4236361077 hasConcept C185592680 @default.

• next